When a Tuesday morning report hit the wire that U.S. Senate Majority Leader Chuck Schumer planned to introduce a bill on Wednesday that decriminalizes marijuana, cannabis stocks posted some solid gains, up as much as 15%. The high didn’t last.
By the closing bell, only two U.S.-traded cannabis-related stocks traded more than 1% higher for the day, although all but one closed up a bit. The big winner was OrganiGram, which closed with a gain of nearly 11% for the day, primarily due to a solid earnings report and an improved outlook announced earlier in the day.
Schumer’s proposed legislation would remove marijuana’s listing as a Schedule I drug under the Controlled Substances Act, the same category as heroin and cocaine, among others. The federal government would regulate and tax the cannabis industry while leaving states in control of how they operate cannabis businesses and regulate adult use of the drug. There would no longer be a federal threat of punishment for possession and use of cannabis products.
If the federal legislation is enacted, marijuana businesses also would gain access to federally regulated banking services that have been withheld due to fears that banks would lose their federal licenses.
Proponents of decriminalizing marijuana no doubt think that the legislation is long overdue. Medical marijuana use has been legalized in 37 states and recreational marijuana use has been approved in 18 states and the District of Columbia.
Share prices of cannabis-related stocks already may have priced in U.S. legalization. Following the November elections that left Democrats in (fragile) control of the White House and Congress, many people believed it was only a matter of time before marijuana was decriminalized.
Another limiting factor on share prices is the experience of legal sales of recreational marijuana products in states where they are already legal. Regulations and taxes make marijuana more expensive when purchased legally than when purchased from a non-legal source. Business owners have pleaded for more enforcement, but the impact of tougher enforcement has been limited. How Schumer’s proposed legislation deals with this issue could be key.
Here’s a sampling of the difference between share price increases of some marijuana companies at around 10:00 a.m. ET Tuesday and the closing price for the day.
| Company | 10 am (%) | Close (%) |
|---|---|---|
| OrganiGram | 15.32 | 10.94 |
| Tilray | 6.77 | 0.49 |
| Aurora Cannabis | 6.00 | 0.48 |
| SunDial | 5.61 | 1.20 |
| Canopy Growth | 5.32 | −0.54 |
| Cronos | 5.29 | 0.87 |
Are You Still Paying With a Debit Card?
The average American spends $17,274 on debit cards a year, and it’s a HUGE mistake. First, debit cards don’t have the same fraud protections as credit cards. Once your money is gone, it’s gone. But more importantly you can actually get something back from this spending every time you swipe.
Issuers are handing out wild bonuses right now. With some you can earn up to 5% back on every purchase. That’s like getting a 5% discount on everything you buy!
Our top pick is kind of hard to imagine. Not only does it pay up to 5% back, it also includes a $200 cash back reward in the first six months, a 0% intro APR, and…. $0 annual fee. It’s quite literally free money for any one that uses a card regularly. Click here to learn more!
Flywheel Publishing has partnered with CardRatings to provide coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.